review of literature on clinical pancreatology - The Pancreapedia

391. Chen JY, Amos CI, Merriman KW, Wei QY, Sen S, Killary AM, Frazier ML. Genetic variants <strong>of</strong>p21 and p27 and pancreatic cancer risk in non-hispanic whites: a case-control study. Pancreatology2009; 9: 1-4.392. Taii A, Hamada S, Kataoka K, Yasukawa S, Sonoyama T, Okanoue T, Yanagisawa A.Correlations between p53 gene mutations and histologic characteristics <strong>of</strong> pancreatic ductalcarcinoma. Pancreas 2009; 38: e60-7.393. Ma J, Jiang Y, Jiang Y, Sun Y, Zhao X. Expression <strong>of</strong> nerve growth factor and tyrosine kinasereceptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol 2008;23: 1852-9.394. Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin F, Srinouanprachanh S,Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA. Association between the peroxisomeproliferator-activated receptor-gamma Pro12Ala variant and haplotype and pancreatic cancer in ahigh-risk cohort <strong>of</strong> smokers: a pilot study. Pancreas 2009; 38: 631-7.395. Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C, Ströbel P.Amplification <strong>of</strong> the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreaticcarcinomas identifies a clinically high-risk group. Am J Pathol 2009; 174: 2246-53.396. Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, Tomita Y, Uehara R,Takehara A, Nakamura Y, Nakagawa H. Serum REG4 level is a predictive biomarker for the responseto preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 2009; 38: 791-8.397. Fernandes-Santos, Caroline MSc; Evangelista Carneiro R, de Souza Mendonca L, BarbosaAguila M, Alberto Mandarim-de-Lacerda C. Rosiglitazone aggravates nonalcoholic fatty pancreaticdisease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas 2009; 38: e80-6.398. Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB,Schally AV, Susini C, Pyronnet S, Bousquet C. Thrombospondin-1 is a critical effector <strong>of</strong>oncosuppressive activity <strong>of</strong> sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA2009; 106: 17769-74.399. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C,Delisle MB, Cuvillier O, Susini C, Bousquet C. Targeting the sphingolipid metabolism to defeatpancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009; 8:809-20.400. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, Tanabe M, Aiura K, KawakamiT, Ogiwara A, Kosuge T, Kitajima M, Kitagawa Y, Sakamoto M. Synuclein-gamma is closely involvedin perineural invasion and distant metastasis in mouse models and is a novel prognostic factor inpancreatic cancer. Clin Cancer Res 2009; 15: 2864-71.401. Kubo T, Kuroda Y, Kokubu A, Hosoda F, Arai Y, Hiraoka N, Hirohashi S, Shibata T.Resequencing analysis <strong>of</strong> the human tyrosine kinase gene family in pancreatic cancer.Pancreas 2009; 38: e200-6.402. Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C, Ströbel P.Amplification <strong>of</strong> the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreaticcarcinomas identifies a clinically high-risk group. Am J Pathol 2009; 174: 2246-53.403. Xue A, Xue M, Jackson C, Smith RC. Suppression <strong>of</strong> urokinase plasminogen activator receptorinhibits proliferation and migration <strong>of</strong> pancreatic adenocarcinoma cells via regulation <strong>of</strong> ERK/p38signaling. Int J Biochem Cell Biol 2009; 41: 1731-8.404. Neale RE, Youlden DR, Krnjacki L, Kimlin MG, van der Pols JC. Latitude variation in pancreaticcancer mortality in Australia. Pancreas 2009; 38: 387-90.